The Types segment classifies kits by detection technology, principally ELISA‑based, fluorescence‑based, and lateral‑flow assay formats. ELISA‑based kits dominate the market because they combine established laboratory workflows with quantitative readouts, supporting high‑throughput testing in central laboratories and thereby generating the bulk of unit sales. Fluorescence‑based kits offer enhanced sensitivity and lower limits of detection, appealing to specialized centers that require early‑stage infection identification; this premium positioning yields higher per‑unit margins despite lower volume. Lateral‑flow assay kits provide point‑of‑care capability, enabling rapid bedside decisions in intensive‑care units and remote settings, which expands market reach into ambulatory and resource‑limited environments. Each technology contributes distinct revenue streams: ELISA drives volume, fluorescence adds value‑added pricing, and lateral flow fuels geographic diversification. The interplay of these type categories shapes the overall market dynamics, influencing R&D investment, pricing strategies, and competitive positioning within the Fungal (1-3)-β-D Glucan Detection Kit segmentation framework. Regulatory approvals and reimbursement pathways further differentiate these types, steering adoption rates across hospital tiers.
